Haisco Pharmaceutical Group (002653) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached ¥1.56 billion, up 75.33% year-over-year, driven by a major technology transfer income.

• Net profit attributable to shareholders surged to ¥554.61 million, a 1,089.85% increase year-over-year.

• Cash flow from operating activities rose sharply to ¥348.49 million, up 1,802.02% year-over-year.

Financial highlights

• Basic and diluted EPS were ¥0.5, up from ¥0.04 in Q1 2025.

• Gross margin improved as revenue growth outpaced cost increases.

• Total assets at quarter-end were ¥7.66 billion, up 9.26% from year-end 2025.

• Shareholders’ equity increased 12.93% to ¥4.84 billion.

Outlook and guidance

• Increased R&D investment signals a focus on long-term competitiveness.

• Management expects continued benefit from technology transfer and government support.